Bli medlem
Bli medlem

Du är här


AbCellera: AbCellera and MassBiologics Partner to Discover Fully Human Antibodies Against Drug-Resistant Bacteria

New collaboration targeting hospital-acquired infections follows on
AbCellera's success in two previous DARPA-funded collaborations with

VANCOUVER, British Columbia, July 20, 2016 (GLOBE NEWSWIRE) -- AbCellera
Biologics Inc., a biotechnology company specializing in the rapid discovery
of monoclonal antibodies from natural immune cells, today announced its third
antibody discovery collaboration with MassBiologics of the University of
Massachusetts Medical School.

This new collaboration, funded by the Defense Advanced Research Project Agency
(DARPA) under the ADEPT-PROTECT program, focuses on addressing the
rapidly-growing, unmet global health threat caused by the multidrug resistant
bacteria,Klebsiella pneumoniae
. This pathogen is among the leading causes of hospital-acquired (nosocomial)
infections worldwide, and has emerged as a major concern for patients.
AbCellera will apply its single-cell antibody discovery platform to identify
panels of antibody candidates against Klebsiella pneumoniae
directly from human volunteers.

"AbCellera's technology has the throughput, speed and capacity to deeply
screen natural human antibody responses to these pathogens," said Carl
Hansen, CEO and co-founder of AbCellera. "We are pleased at the opportunity
to expand our collaboration with MassBiologics, and believe this work will
further demonstrate the strength of our approach for rapid human antibody
discovery, immune profiling, and vaccine development."

This partnership builds on the successes of two earlier DARPA-funded
collaborations between AbCellera and MassBiologics, from which novel
antibodies for potential therapeutics to enterotoxigenic E. coli
and Ebola virus were discovered.

About AbCellera Biologics Inc.

AbCellera is a privately held biotechnology company that provides enabling
technologies for the discovery and development of monoclonal antibody (mAb)
therapies directly from natural immune cells.

AbCellera's lead technology is a proprietary single cell antibody discovery
platform that provides pharma and biotech partners with the ability to
rapidly identify mAb therapeutic candidates from the natural immune
repertoires of any species, including humans. For more information, please

About MassBiologics

MassBiologics of the University of Massachusetts Medical School is the only
publicly owned, non-profit FDA-licensed manufacturer of vaccines and other
biologic products in the United States. The laboratory was established in
1894 by the state Board of Health to produce diphtheria antitoxin. Since that
time, the focus at MassBiologics has been to improve public health through
applied research, development and production of biologic products. In 1997,
the Commonwealth of Massachusetts transferred MassBiologics operations from
the Department of Public Health to UMass Medical School to "maintain their
public purpose, preserving their ability to compete in an increasingly
competitive marketplace and to maximize their value to the Commonwealth."

About the University of Massachusetts Medical School

The University of Massachusetts Medical School has built a reputation as a
world-class research institution, consistently producing noteworthy advances
in clinical and basic research. The Medical School attracts more than $270
million in research funding annually, 80 percent of which comes from federal
funding sources. The mission of the Medical School is to advance the health
and well-being of the people of the commonwealth and the world through
pioneering education, research, public service and health care delivery with
its clinical partner, UMass Memorial Health Care. For more information,

Media Contacts

Kevin Heyries
Telephone: 604-827-4151


This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AbCellera via Globenewswire


Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.